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Abstract
Background:  Serum paraoxonase (PON1) is a high density lipoprotein (HDL)-associated enzyme
involved in organophosphate (OP) degradation and prevention of atherosclerosis. PON1 comprises a
potential candidate for in vivo therapeutics, as an anti-atherogenic agent, and for detoxification of pesticides
and nerve agents. Because human PON1 exhibits limited stability, engineered, recombinant PON1
(rePON1) variants that were designed for higher reactivity, solubility, stability, and bacterial expression,
are candidates for treatment. This work addresses the feasibility of in vivo administration of rePON1, and
its HDL complex, as a potentially therapeutic agent dubbed BL-3050.
Methods: For stability studies we applied different challenges related to the in vivo disfunctionalization of
HDL and PON1 and tested for inactivation of PON1's activity. We applied acute, repetitive
administrations of BL-3050 in mice to assess its toxicity and adverse immune responses. The in vivo efficacy
of recombinant PON1 and BL-3050 were tested with an animal model of chlorpyrifos-oxon poisoning.
Results: Inactivation studies show significantly improved in vitro lifespan of the engineered rePON1
relative to human PON1. Significant sequence changes relative to human PON1 might hamper the in vivo
applicability of BL-3050 due to adverse immune responses. However, we observed no toxic effects in mice
subjected to repetitive administration of BL-3050, suggesting that BL-3050 could be safely used. To further
evaluate the activity of BL-3050 in vivo, we applied an animal model that mimics human organophosphate
poisoning. In these studies, a significant advantages of rePON1 and BL-3050 (>87.5% survival versus
<37.5% in the control groups) was observed. Furthermore, BL-3050 and rePON1 were superior to the
conventional treatment of atropine-2-PAM as a prophylactic treatment for OP poisoning.
Conclusion: In vitro and in vivo data described here demonstrate the potential advantages of rePON1 and
BL-3050 for treatment of OP toxicity and chronic cardiovascular diseases like atherosclerosis. The in vivo
data also suggest that rePON1 and BL-3050 are stable and safe, and could be used for acute, and possibly
repeated treatments, with no adverse effects.
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Background
Serum paraoxonase (PON1) is a calcium-dependent lac-
tonase, with lipophilic lactones constituting its primary
substrates [1-3]. When associated with HDL, an increase
in the stability and lipo-lactonase activity of PON1 were
measured both in vivo and in vitro [4,5]. Also, HDL-PON1
complex inhibits LDL oxidation [6,7], and stimulates cho-
lesterol efflux from macrophages [8]. Previous studies of
PON1 showed that knockout mice were highly suscepti-
ble to atherosclerosis [9], and serum PON1 levels, and
polymorphism, were related to the level of cardiovascular
disease [10,11], all of which indicate a role of PON1 for
the prevention of atherosclerosis. PON1 also exhibits
hydrolytic activity against certain organophosphates
(OPs), including the toxic oxon metabolites of a number
of insecticides, and nerve agents such as sarin and soman
[12,13], and has thus the potential to protect against OP
poisoning. Indeed, PON1 knockout mice exhibit a signif-
icant increase in sensitivity to diazoxon [14], paraoxon,
chlorpyrifos and chlorpyrifos-oxon [9], and the toxic
effects can be reversed by administrating rabbit PON1
[15]. Although these properties render PON1 an attractive
candidate for the treatment of atherosclerosis, and pesti-
cides or nerve agents toxicity, certain characterizations of
human PON1 hamper such uses.
Human PON1 (huPON1), is sensitive to a range of chal-
lenges, including the presence of oxidizing agents, glu-
cose, and thiols [16-19]. The complex of HDL (specifically
apoA-I), stabilizes the enzyme. Thus, when anchored onto
functional HDL-apoA-I, PON1 exhibits anti-atherogenic
activity [20], but not in its lipid-free form [21,22]. How-
ever, cardiovascular disease (CVD) involves the modifica-
tion of HDL composition and structure giving rise to
"dysfunctional HDL" [23]. HDL-associated enzymes
including PON1 become dysfunctional and/or depleted
under these conditions, as well as under inflammatory
conditions [24], and metabolic diseases such as type 1 and
type 2 diabetes [23,25], metabolic syndrome (MetS) [26],
and premature CVD [27].
Acute-phase response is also associated with decreased
PON1 activity, probably due to the displacement of
PON1 from HDL [26]. It appears, therefore, that a highly
robust PON1, and perhaps a regeneration of HDL parti-
cles, might be needed for therapeutic applications, as
demonstrated by the application of apoA-I Milano [28]
and apoA-I mimetics [29]. The application of HDL-PON1
complex with improved stability and efficacy as described
in this paper might therefore be needed for effective HDL-
therapy.
In addition, the catalytic efficiency of huPON1 with most
organophosphates, and effectively all highly toxic nerve
agents, is not sufficiently high to provide substantial pro-
tection [14,30]. In fact, PON1's activity with many OPs is
comparable to the weak, promiscuous activity of serum
albumin towards these agents [31]. Another limitation of
huPON1 is its poor stability and tendency for aggregation
[32,33]. This may limit the therapeutic usages of the
enzyme in which relatively high concentrations are
administered by the intravenous route.
Directed evolution is extensively used to improve protein
properties, such as stability, binding affinity, or catalytic
efficiency. We have applied directed evolution to generate
recombinant PON1 (rePON1) that expresses in a soluble
and functional form in E. coli, and exhibits enzymatic
properties, and HDL binding and stimulation capabilities,
that are essentially identical to those of huPON1 [34,35].
The often-used rePON1 variant G3C9 is closest in
sequence to rabbit PON1 (94% amino acid identity) and
huPON1 (85% identity). RePON1-G3C9 has also pro-
vided the basis for the directed evolution of other recom-
binant variants that exhibit 10 to 380-fold higher catalytic
efficiencies with various toxic OPs relative to huPON1
[13,36,37]. The therapeutic potential of in vitro evolved
proteins, has been convincingly demonstrated with anti-
bodies and antibody fragments [38], but is far less devel-
oped with enzymes [39]. Of particular concern is the
toxicity of engineered proteins such as rePON1 whose
sequence differs from the human protein.
In this study we examined the in vitro stability of rePON1
as a purified protein or in a complex with reconstituted
HDL (rePON1-HDL), and compared them to huPON1,
and huPON1-HDL (huHDL). We used various conditions
that mimic physiologically relevant challenges leading to
dysfunctional HDL. The results indicate significantly
higher stability and reactivity of rePON1 and rePON1-
HDL when compared to huPON1 and huHDL, and sug-
gest that rePON1 and rePON1-HDL may exhibit an
improved potential for in vivo treatments. To further
address the issue of in vivo applicability, we generated
reconstituted complexes of rePON1 with apoA-I and the
phospholipids POPC (dubbed BL-3050) and evaluated
the potential toxicity of BL-3050 by single administration
to mice, and by repeated administrations in the course of
two weeks, and observed no adverse effects. Finally, to
examine whether BL-3050 is active in vivo, we applied an
animal model for OP poisoning. BL-3050 and purified
rePON1 were administrated few minutes, or 14 hours,
prior to chlorpyriphos-oxon (CPO) poisoning to evaluate
their protection abilities. Both, BL-3050 and rePON1
showed a significant protective effect in vivo. These results
indicate that rePON1, and BL-3050, could be applied in
vivo while taking advantage of the improved stability and
catalytic efficiencies of rePON1 variants.BMC Clinical Pharmacology 2009, 9:18 http://www.biomedcentral.com/1472-6904/9/18
Page 3 of 13
(page number not for citation purposes)
Methods
Materials
1-Palmitoyl-2-Oleoyl-Phosphatidyl Choline (POPC) was
purchased from Avanti Polar Lipids (Alabaster, AL, USA).
Free cholesterol (FC) was from Sigma-Aldrich (Israel).
Sodium hypochlorite (NaOCl, 6%) was from Gadot Lab.
Supplies (Israel). Bio-Beads SM-2 was from Bio-Rad (Her-
cules, CA, USA). Chlorpyrifos oxon was from Greyhound
Chromatography and Allied Chemicals (Birkenhead,
UK). Atropine was from Teva (Israel), and 2-pyridine
aldoxime methyl chloride (2-PAM) was purchased from
Sigma-Aldrich (Israel). All chemicals were of the highest-
purity analytical grade.
PON1 preparation
Recombinant PON1 variant rePON1-G3C9 (gi:
40850544) carrying a 8xHis tag at the C-terminus, was
expressed and purified as described [35]. Re-PON1 was
stored in the storage buffer (50 mM Tris pH 8.0, 50 mM
NaCl, 1 mM CaCl2 and 0.1% tergitol). Human PON1
(192Q) was kindly provided by Prof. Michael Aviram
(Technion, Israel) and Dr. Dragomir Draganov (WIL
Research Laboratories, Ashland, OH) and was stored with
20% glycerol. The enzyme was purified from pooled
blood sera of healthy individuals by three sequential gel
chromatographic steps: Cibacron Blue 3GA, DEAE I, and
DEAE II as described [40]. The huPON1 sample applied
here had a specific arylesterase activity of ~1000 U/mg (1
U = 1 μmol of phenyl acetate hydrolyzed per minute per
mg protein at 1 mM substrate concentration), as previ-
ously reported [41], and SDS-polyacrylamide gel electro-
phoresis indicated a single band (≥ 90% protein purity).
In all the assays rePON1 and huPON1 (stock concentra-
tions ~1 mg/ml) were similarly diluted in Tris-buffered
saline (TBS; 10 mM Tris pH 8.0, 150 mM NaCl) while
keeping the same final percentage of tergitol in all sam-
ples. All the data represents the mean and S.D. obtained
from at least three independent experiments.
Human HDL preparation
Human HDL (192Q) was kindly provided by Prof.
Michael Aviram (Technion, Israel). HDL was derived from
normolipidemic human volunteers by discontinuous
density gradient ultracenrifugation [42]. The HDL sample
was dialyzed against TBS with 1 mM CaCl2, and its protein
content was determined with the Folin phenol reagent.
rePON1-HDL preparation for in vitro studies
Discoidal reconstituted HDL (rHDL) containing POPC,
FC and apoA-I at a starting molar ratio of 100/5/1, were
prepared by the cholate dialysis method as previously
described [35]. The homogeneity of the preparations was
assessed by non-denaturing gradient gel electrophoresis
(4-20% polyacrylamide, Pharmacia) and electron micros-
copy indicating the formation of particles of ~10 nm
[43,44]. RePON1 was freshly delipidated using Bio-Beads,
diluted to 0.1 μM in the assay buffer, and incubated with
a 100-fold molar excess of rHDL (10 μM of rHDL; 0.6 mg/
ml apoA-I).
PON1 in vitro inactivation by calcium chelation
PON1 and PON1-HDL samples were diluted in TBS with
1 mM CaCl2 to a final PON1 concentration of ~0.1 μM.
An equal volume of inactivation buffer (4 mM EDTA and
8 mM β-mercaptoethanol in 50 mM Tris, pH 8.0) was
added, and samples were incubated at 37°C. At different
time points, aliquots of the reaction mixtures were diluted
40-fold in activity buffer (50 mM Tris pH 8.0, 1 mM
CaCl2), and the residual PON1 activity was determined
with 2 mM phenyl acetate. The resultant inactivation rates
were fitted to either mono- or double-exponentials
[35,45]. PON1 inactivation in the absence of calcium che-
lator was examined by testing the residual activity after the
incubation of PON1 and PON1-HDL samples in phos-
phate-buffered saline (PBS) supplemented with 1 mM
CaCl2 for 24 hrs at 37°C.
PON1 in vitro thermal inactivation
RePON1 and huPON1 (~1 μM) were incubated in TBS
with 1 mM CaCl2 at a range of temperatures (25 - 80°C)
for 30 mins. The samples were briefly cooled on ice,
diluted 10-fold in activity buffer, and the residual PON1
activity determined with 2 mM phenyl acetate at 25°C.
Data were fitted to a sigmoidal decay function and the
apparent mid-melting temperature values (Tm) were
derived. Residual activity (%) = 100/(1 + exp(m*(T-Tm));
whereby T is the temperature, and m is a constant. Sepa-
rate fits for rePON1 and huPON1 were obtained while
masking the first point that showed a non-regular decline
and corresponded to a loss of ~20% of activity at relatively
low temperature (30°C for human PON1, and 40°C for
G3C9). The data sets were then normalized to 100% at the
lowest temperature, so that the rePON1 and huPON1
plots could be overlayed and fitted. The Tm values were
not affected by this normalization.
PON1 in vitro inactivation by glutathione
PON1 and PON1-HDL samples were incubated at 37°C
at PON1 concentrations of ~0.1 μM in TBS supplemented
with 1 mM CaCl2 and various glutathione (GSH) concen-
trations (0 - 20 mM), or various GSH/GSSG ratios using a
constant total glutathione concentration (GSH plus
2xGSSG) of 10 mM. Following 40 minutes incubation,
the reaction mixtures were diluted 40-fold in activity
buffer, and residual PON1 activity was determined with 2
mM phenyl acetate.
PON1 in vitro oxidation by hypochlorite
Hypochlorite oxidation was performed as described [46]
with certain modifications. PON1 and PON1-HDL oxida-BMC Clinical Pharmacology 2009, 9:18 http://www.biomedcentral.com/1472-6904/9/18
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tion was performed with NaOCl in 10 mM phosphate
buffer (pH 8.0) that was preincubated with 100 μM
nitrilotriacetic acid (NTA) for 12 hrs at 25°C (this pre-
incubation aimed at chelating the traces of transition
metal ions that may enhance the oxidation reactions),
and then supplemented with 1 mM CaCl2. PON1 (0.1
μM) and HDL (5 μM) samples were incubated with a
range of NaOCl concentrations (0 - 200 μM) for 24 hrs at
37°C. The reaction mixtures were subsequently diluted
40-fold in activity buffer, and the residual PON1 activity
was determined with 2 mM phenyl acetate. It should be
noted that the reproducibility of these oxidation assays
was limited, although consistent differences between the
recombinant and human PON1 and HDL complexes were
observed in all the assays. It appears that these oxidative
assays are very sensitive to the presence of the traces of the
transition metal ions in the assay buffer. Indeed, pre-incu-
bating the buffer with NTA (100 μM) gave more reproduc-
ible results.
PON1 in vitro oxidation by Tetranitromethane (TNM)
PON1 and PON1-HDL samples were diluted in PBS (~0.1
μM of PON1 and ~5 μM of HDL) supplemented with 1
mM CaCl2 and 0.01% tergitol. Inactivation was initiated
by addition of TNM (1 mM final concentration) and incu-
bation of the samples at 37°C. At different time points (0,
0.25 and 0.5 hrs), aliquots of the reaction mixtures were
taken, diluted 40-fold in activity buffer, and the residual
PON1 activity was determined with phenyl acetate as
above.
BL-3050 preparation for in vivo studies
The standard cholate dialysis protocol for the preparation
of rHDL [35,43,44] was optimized for large-scale produc-
tions of in vivo applicable material. RePON1 and human
apoA-I [47] were expressed in E. coli as described [35]. The
proteins were purified to a high degree of homogeneity by
fast performance liquid chromatography (FPLC) on a Ni-
NTA column, followed by a High Trap Q column (Phar-
macia). The endotoxins level of the purified proteins was
assayed with Gel Clot kit by BioWhittaker Cambrex.
POPC-apoA-I mixtures were prepared by suspending
POPC (1 gr) and apoA-I (0.32 gr) in TBS with 2% sodium
deoxycholate. The resultant mixture was vigorously vor-
texed and sonicated until a clear solution was obtained.
POPC-apoA-I mixture was then incubated with the freshly
delipidated re-PON1 (0.16 gr) to yield rePON1-POPC-
apoA-I mixture. The resultant mixture was extensively
diluted in TBS to remove sodium cholate, and concen-
trated by ultrafiltration to yield discoidal rePON1-POPC-
apoA-I complexes at the final concentration of the com-
ponents of 2 mg/ml, 12.5 mg/ml and 4 mg/ml, respec-
tively, in a dosage volume lower than 10 ml/kg.
In vivo studies
All in vivo studies were performed at HBI (Harlan Biotech,
Israel) following the review of the Committee for Ethical
Conduct in the Care and Use of Laboratory Animals of the
Hebrew University, Jerusalem, the Institutional Animal
Care and Use Committees (IACUC) responsible for
approving HBI animal usage applications and regulations
set forth, and in compliance with its respective registra-
tion under: NIH accreditation No.: OPR-A01-5011 HU.
The ethic approvals for intravenous toxicity in mice (sin-
gle dose acute toxicity and two-week repeated toxicity)
and organophosphate detoxification studies are MD-07-
10470-5 and MD-08-11201-5, respectively.
BL-3050 single dose acute intravenous (IV) toxicity in mice
Potential toxic effects of BL-3050 (60 mg/kg) were exam-
ined following a single intravenous injection to the tail
vein at a dose volume of 0.2 mL to male and female
C57BL/6J mice. Two additional groups comprised of TBS
or POPC were evaluated under identical experimental
conditions and served as the control groups. All groups
comprised  n  = 6  mice/group (3 males and 3 females)
excluding TBS group which consisted of n = 4 mice/group
(2 males and 2 females). All animals were closely
observed for signs of adverse effects and toxicity during
the first 24 hours and were sacrificed after 4 days.
BL-3050 two-week repeated intravenous (IV) toxicity in 
mice
Repeat dose toxicity of BL-3050 (60 mg/kg) was assessed
following 7 intravenous injections to the tail vein at a
dose volume of 0.2 mL to male & female C57BL/6J mice,
carried out every other day during the entire two-week
study period. Two additional groups comprised of TBS or
POPC were evaluated under identical experimental condi-
tions and served as the control groups. All groups com-
prised of n = 10 mice/group (5 males and 5 females). All
animals were observed closely for signs of adverse effects
during the two-week study period until animals were sac-
rificed.
All animals from both studies (single dose acute toxicity
and two-week repeated toxicity) were subjected to a full
detailed necropsy and gross pathological examination at
termination time. Furthermore, selected target organs/tis-
sues (heart, lung, kidney, spleen, liver) were harvested
from all the animals in the study during the scheduled
necropsy, weighed wet as soon as possible following their
dissection and fixed in 10% neutral buffered formalin
(approximately 4% formaldehyde solution) for at least
48-hr fixation period prior to their analysis. Tissues were
trimmed, embedded in paraffin, sectioned at approxi-
mately 5 microns thickness and stained with Hematoxylin
& Eosin (H&E) for histopathological analysis.BMC Clinical Pharmacology 2009, 9:18 http://www.biomedcentral.com/1472-6904/9/18
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Organophosphate detoxification in the animal model
Organophosphate (OP) intoxication was induced by a
single oral gavage (PO) administration of chlorpyrifos-
oxon (CPO) to male C57BL/6J mice (n = 8) at a dose of
23 mg/kg at a dose volume of 10 mL/kg (23 mg/kg was
determined as the LD50 in preliminary studies; oral gavage
was chosen for safety reasons as it minimizes the risk of
leakage from the skin and contamination). The study con-
sisted of the following groups: untreated (where only
CPO was administrated), TBS (buffer only; 0.2 mL),
POPC (2.5 mg/animal), rePON1 (0.4 mg and 0.63 mg/
animal), BL-3050 (0.4 mg rePON1/animal), and atropine
(20 mg/kg) with 2-PAM (25 mg/kg). TBS, POPC, rePON1
and BL-3050 were injected intravenously to the tail vein at
a dose volume of 0.2 mL to mice, and atropine with 2-
PAM were injected to the intraperitoneal (IP) into the pos-
terior abdominal regions at the dose volume of 10 mL/kg.
Treatments with the test article or control were carried out
5 minutes, 3 hr or 14 hours prior to induction of CPO
intoxication as described in Table 1. All animals were
observed closely for clinical signs following CPO intoxica-
tion during the first 24 hours before they were sacrificed.
All clinical signs noted following CPO intoxication were
categorized to mild, moderate or severe reactions. Mild
reactions were characterized by straub tail and/or ataxia
and/or diarrhea. Moderate reactions consisted in addition
decreased motor activity and/or dyspnea while animals
with severe reactions exhibited in addition ventral posi-
tion and/or tremors as well. The overall reactions
observed following CPO intoxication were scored using
semi-quantitative grading of five grades (0-4), taking into
consideration the severity of the reactions (0 = No Reac-
tions, 1 = Mild Reactions, 2 = Moderate Reactions, 3 =
Severe Reactions, 4 = Mortality).
Results and Discussion
Higher stability of rePON1 and rePON1-HDL
PON1 possess two calcium atoms - a highly buried "struc-
tural calcium" that shows high affinity, and the lower-
affinity active-site "catalytic calcium" [48,49]. The deple-
tion of calcium by chelators, or even by dilution in buffers
with no calcium, renders PON1 catalytically inactive by
removing the catalytic calcium, and eventually leads to
loss of the structural calcium and irreversible denatura-
tion of the enzyme [50]. Calcium affinity is correlated
with the overall stability of PON1 [49,50], and may there-
fore reflect the half-life of the enzyme in serum, and/or
when stored. RePON1 exhibits higher calcium affinity,
possibly by virtue of its closer similarity to rabbit PON1
[49,50], and higher stability altogether, by virtue of the
improved packing of its hydrophobic core mediated by
the mutations acquired in the directed evolution process
[51]. Indeed, a test of inactivation rates in the presence of
EDTA as chelator (Figure 1a) [35], indicated an almost
immediate inactivation of huPON1 (t1/2 = 5 min), in
oppose to slow inactivation of rePON1 (t1/2~5 hrs). The
association with HDL greatly increases the enzyme's sta-
bility, as previously reported [35,45]. Nonetheless,
huHDL shows rather limited stability (t1/2 = 1.3 hrs). In
contrast, the complex of rePON1 with in vitro reconsti-
tuted HDL particles shows no inactivation within the
timescales examined here, and only 21% inactivation
after 24 hrs (t1/2 = 70 hrs) [35].
The higher stability of rePON1 was also apparent in the
absence of specific calcium chelators: huPON1 exhibited
54% inactivation when incubated in phosphate buffer
containing 1 mM CaCl2  for 24 hrs, whereas rePON1
remained intact (Figure 1b). Inactivation of huPON1 after
dilution in PBS was observed in other studies [16,19].
Indeed, huPON1-HDL only preserved its activity in phos-
phate buffer suggesting that the HDL stimulation was
counterbalanced by loss of activity due to calcium loss. In
contrast, rePON1 gained ~30% arylesterase activity due to
enzymatic stimulation by HDL. Although phosphate
interacts with calcium, its ligating affinity (6.3 × 10-3 M)
[52] is far lower than huPON1's (3.6 × 10-7 M) [49].
Hence, the major inactivating force acting in this experi-
ment is the dilution of lipids, and loss of conformational
stability. The improved conformational stability of
rePON1 was also apparent in the results of the standard
test of protein stability by thermal denaturation: rePON1
shows >13°C higher melting temperature than huPON1
(Figure 2). The higher conformational stability of rePON1
may give it higher resistance against the cumulative dam-
age of different challenges that inactivate PON1 and HDL
in vivo, as suggested by the results presented below.
Inactivation by physiologically-related challenges
We tested several reagents that have been shown to inacti-
vate PON1 in relation with various physiological stresses
that induce HDL and/or PON1 inactivation in vivo. The
glutathione redox couple is present in mammalian cells in
concentrations between 1 and 10 mM, with the reduced
form (GSH) predominating the oxidized one (GSSG)
[53]. Glutathione, in both its reduced and oxidized forms,
was shown to mediate PON1 inactivation, possibly by
reacting with PON1's disulphide bond, or free cysteine
[18,54]. Indeed, oxidative stress is characterized by
changes in glutathione concentrations and decreased
reduced/oxidized ratios (GSH/GSSG) in the range of 10 to
1 [55]. In healthy humans, plasma glutathione is present
at ~1 mM concentrations, while enhanced protein glu-
tathiolation is associated with increased oxidative stress
[56]. The increased GSH and GSSG concentrations
applied here for short incubations (40 mins), may also
reflect damages that occur in vivo at lower concentration
yet on much longer time scales (weeks, or months).
Indeed, GSSG was shown to induce the loss of PON1 andBMC Clinical Pharmacology 2009, 9:18 http://www.biomedcentral.com/1472-6904/9/18
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HDL activity (including the ability to mediate macro-
phage cholesterol efflux) in a dose-dependent manner
[18]. Similar results were obtained here for huPON1,
although rePON1 showed much lower sensitivity under
these conditions (Figure 3). The huPON1-HDL complex
shows essentially the same inactivation rate as huPON1,
but the reconstituted rePON1-HDL complex does provide
improved protection against oxidized glutathione (Figure
3a). At 10 mM GSSG, huPON1 and huHDL totally lost
their activity, whereas significantly higher activity was
retained in the rePON1 and rePON1-HDL samples (40%
and 80%, respectively). A mixture of reduced and oxi-
dized glutathione at 10-100 ratio (10 mM total glutath-
ione), induced human PON1 and huHDL inactivation at
a higher rate than oxidized glutathione on its own. None-
theless, rePON1 and rePON1-HDL proved highly resist-
Table 1: representative results of detoxification studies
Time prior CPO induction Group1 Score Mortality
(%)
Severe reaction
(%)
untreated2 3.6 62.5 37.5
TBS 3.8 75 25
POPC 3.9 87.5 12.5
5 min
Atropine+2PAM3 0.5* 0 0
BL-30504 1.3* 12.5 0
3 hours
Atropine+2PAM3 2.1 25 12.5
BL-30504 1.3* 12.5 0
rePON1-TBS4 1.4* 12.5 12.5
14 hours
BL-30504 3.0 50 25
rePON1-TBS4 1.8* 0 12.5
rePON1-TBS5 1.1* 12.5 12.5
Single oral gavage of CPO (23 mg/kg, 10 mL/kg dose) to male C57BL/6J mice was preceded (5 min, 3 hr or 14 hrs prior to CPO intoxication) by no 
treatment or by injection of TBS (buffer only), POPC (2.5 mg/animal), rePON1 (0.4 mg and 0.63 mg/animal), BL-3050 (0.4 mg rePON1/animal), and 
atropine (20 mg/kg) with 2-PAM (25 mg/kg). Animals were observed closely for clinical signs during the first 24 hours following CPO intoxication.
* - Significant difference (p < 0.05) compared to all control groups using Mann-Whitney test (see Methods and Results and Discussion sections for 
more details).
1 - All groups comprised of 8 mice
2 - Mice were only poisoned by CPO
3 - Atropine and 2-PAM concentrations were 20 mg/kg and 25 mg/kg, respectively
4 - Protein estimation amount for rePON1 was 0.4 mg/animal.
5 - Protein estimation amount for rePON1 was 0.63 mg/animal.BMC Clinical Pharmacology 2009, 9:18 http://www.biomedcentral.com/1472-6904/9/18
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Inactivation of the recombinant and human PON1, and PON1-HDL complexes in the presence of calcium chelator (A) or in  buffer (B) Figure 1
Inactivation of the recombinant and human PON1, and PON1-HDL complexes in the presence of calcium che-
lator (A) or in buffer (B). Data represents mean ± SD of at least 3 independent experiments. A. Inactivation kinetics of 
rePON1, rePON1-HDL, huPON1, and huPON1-HDL (huHDL) by EDTA (4 mM) and β-mercaptoethanol (8 mM) at 37°C. 
Residual activity at various time points was determined by initial rates of phenyl acetate hydrolysis and plotted as percent of 
the activity at time zero. Data were fitted to a single exponential for rePON1-HDL, and to double-exponentials for the remain-
ing samples [35]. B. Inactivation of rePON1, rePON1-HDL, huPON1, and huPON1-HDL (huHDL), in PBS buffer with 1 mM 
CaCl2. Residual PON1 activity after 24 hrs incubation at 37°C is presented as percentage of the initial activity.
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ant against the effects of both reduced and oxidized
glutathione, and their activity remained intact at all the
GSH/GSSG ratios tested (Figure 3b).
Hypochlorite was used to mimic oxidative damages to
HDL that undermine its composition and structural sta-
bility [46]. It is one of the products of myeloperoxidase
(MPO), a heme enzyme expressed by macrophages in
atherosclerotic lesions, and is thought to be a key media-
tor of lipoprotein oxidation [57]. Physiological concentra-
tions of HOCl have not been accurately determined,
although some reports suggest that, at sites of acute
inflammation, the molar ratio of oxidant to HDL may be
as high as 30:1 [46,58]. HDL contains both a protein and
lipid component, either of which may be oxidatively dam-
aged during atherosclerosis [59,60].
Oxidation by hypochlorite led to the dose-dependent
inactivation of PON1 on its own and in complex with
HDL (Figure 4). RePON1-HDL complex showed a signifi-
cantly higher resistance (> 10-fold) to hypochlorite inacti-
vation compared to huHDL (45% and 4% residual PON1
activity at 200 μM HOCl, respectively). In the absence of
HDL, both rePON1 and huPON1 showed increased sen-
sitivity to hypochlorite inactivation. However, rePON1
was approximately 2-fold more resistant to this oxidative
damage than huPON1.
Tetranitromethane (TNM) that leads to nitration of tyro-
sine, cysteine, and methionine residues in proteins, can
also be used to mimic PON1 and HDL oxidation during
oxidative stress [60,61]. Indeed, HDL isolated from
patients with cardiovascular disease contains elevated lev-
els of 3-chlorotyrosine and 3-nitrotyrosine, that are two
characteristic products of MPO [62]. Oxidation by TNM
led to the time-dependent inactivation of PON1, on its
own and in complex with HDL (Figure 5). RePON1-HDL
complex showed a higher resistance to TMN inactivation
compared to huHDL (80% and 65% residual PON1 activ-
ity after 0.5 hr of incubation, respectively). In the absence
of HDL, both rePON1 and huPON1 showed increased
sensitivity to TMN inactivation. However, rePON1 was
approximately 1.5-fold more resistant to this oxidative
damage than huPON1 (65% and 45% residual PON1
activity after 0.5 hr of incubation, respectively). Inactiva-
tion was specific to TNM treatment, and no loss of PON1
activity was observed in control samples containing no
TNM.
Tests of other physiologically relevant agents did not yield
sufficiently meaningful, and/or reproducible, results.
Although PON1 was shown to be inactivated in the pres-
ence of glucose, possibly due to the glycation of lysine res-
idues [16], we observed no specific inactivation by
glucose (up to 100 mM). It appears that the glucose-medi-
ated effects are masked by the rapid inactivation of
huPON1 due to its dilution into buffer (Figure 1b),
whereas rePON1 is relatively resistant to the dilution
effect, as well as to the effects of glucose. Oxidative agents
such as hydrogen peroxide, or tert-butyl peroxide, failed
to induce specific inactivation (i.e., inactivation beyond
the levels of buffer alone) under the conditions applied
here. Competing PON1 binding to rHDL by serum amy-
loid A indicated that rePON1 remained fully associated
with HDL in presence of the highest concentrations tested
(2 mg/ml). In contrast, huPON1 was readily displaced
from HDL and thereby became inactivated (data not
shown). However, the observed inactivation of huPON1
may in part be ascribed to loss of activity following long
incubations in buffer as described above.
BL-3050 toxicity in mice
To assess the potential toxic effects of BL-3050, a single
intravenous injection (IV) to C57BL/6J mice was per-
formed (acute study) and the effects were compared to the
vehicle control groups of TBS, and TBS with POPC. All
animals were observed closely for signs of adverse effects
(see Methods), and were subjected to a full necropsy on
termination day. The results indicated no toxic effects, or
adverse immune responses, as indicated by the his-
Heat inactivation of rePON1 and huPON1 Figure 2
Heat inactivation of rePON1 and huPON1. Purified 
enzymes diluted in TBS with 1 mM CaCl2 were incubated at 
the range of temperatures (25 - 80°C) for 30 mins, and resid-
ual PON1 activity was determined. Data were fitted to the 
sigmoidal decay function to give Tm values of 47.2°C for 
huPON1 and 60.4°C for rePON1 (the corresponding m val-
ues are 0.273 and 0.399; see Methods). Each point represents 
mean ± SD of 3 experiments.
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Inactivation of the recombinant and human PON1, and PON1-HDL complexes by glutathione Figure 3
Inactivation of the recombinant and human PON1, and PON1-HDL complexes by glutathione. Data represents 
mean ± SD of at least 3 independent experiments. A. Recombinant and human PON1, and the corresponding HDL complexes, 
were incubated with increasing concentrations of GSSG at 37°C. Residual PON1 activity was determined after 40 min of incu-
bation, and plotted as percentage of the initial activity. B. Recombinant and human PON1, and the corresponding HDL com-
plexes, were incubated with various GSH/GSSG ratios (the ratios are expressed as the ratio of glutathione equivalents, i.e., the 
ratio of GSH to 2xGSSG) whilst keeping the total glutathione concentration at 10 mM. Residual PON1 activity was determined 
after 40 min of incubation, and plotted as percentage of the initial activity.
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topathological analysis. We subsequently assessed the
potential toxic effects of BL-3050 with respect to its
intended use as treatment for atherosclerosis. Repeated IV
injections to C57BL/6J mice were carried out every other
day during a period of two weeks. Two equally sized
groups, subjected to either TBS, or POPC, under identical
experimental conditions served as control groups. All
groups comprised 10 mice (5 males and 5 females). Ani-
mals were observed closely for signs of adverse effects
and/or mortality during the 14-day injection period. The
results indicated no mortality, or any other conspicuous
treatment-related adverse reactions, in any of the tested
animals throughout this period. No gross pathological
findings were evident macroscopically among the injected
animals supported by histopathological analysis and no
changes in mean group organ weight values were
observed. These results suggest that BL-3050 injected
intravenously (IV) every other day during two weeks can
be considered a safe treatment.
In vivo efficacy of rePON1 and BL-3050
We examined the possibility of in vivo treatment with
rePON1, and BL-3050 (reconstituted complexes of
rePON1, apoA-I and POPC) using mice as a model. HDL-
like particles were produced from recombinant apoA-I
[47] and POPC. The standard cholate dialysis protocol
[35,43,44] was optimized towards large-scale production
of in vivo applicable material, while excluding cholesterol
from this composition aimed at potential therapy of CVD.
The injected amounts of apoA-I-POPC were selected to
match the amounts applied with apoA-I Milano in
patients trials [63], and PON1 was added to the complex
at 1:2 molar ratio relative to apoA-I. Although higher
ratios (≥ 1:20) can induce higher stability and stimulation
[35], these would have dictated impossibly high amounts
of apoA-I-POPC. In addition, ex vivo studies indicated that
1:2 PON1:apoA-I ratios are sufficient to induce marked
effects of cholesterol macrophage efflux and LDL oxida-
tion [21]. The concentrations of rePON1, and rePON1-
HDL, were adjusted to fit a volume dosage of 10 mL/kg.
As a preliminary measure of in vivo applicability, we
applied the widely used chlorpyrifos-oxon (CPO) toxicity
model [15]. CPO intoxication was induced by administra-
tion of CPO at a dose level of 23 mg/kg (10 mL/kg) by sin-
gle oral gavage to male C57BL/6J mice. The selection of 23
mg/kg dose was based on preliminary CPO studies where
this dose was determined as the LD50 (data not shown).
This dose induced mortality incidence of ≥ 50%, and all
Inactivation of the recombinant and human PON1, and  PON1-HDL complexes by hypochlorite Figure 4
Inactivation of the recombinant and human PON1, 
and PON1-HDL complexes by hypochlorite. Recom-
binant and human PON1, and the corresponding HDL com-
plexes, were incubated with increasing concentrations of 
hypochlorite at 37°C. Residual PON1 activity was deter-
mined after 24 hrs incubation, and plotted as percentage of 
the initial activity. Residual PON1 activity in the absence of 
hypochlorite remained largely unchanged for all the samples 
(≥ 75%). Data represents mean ± SD of 4 independent 
experiments.
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Inactivation of recombinant and human PON1, and PON1- HDL complexes by tetranitromethane Figure 5
Inactivation of recombinant and human PON1, and 
PON1-HDL complexes by tetranitromethane. PON1 
samples were incubated with 1 mM of TNM at 37°C. Resid-
ual PON1 activity was determined after 0.25 and 0.5 hrs of 
incubation, and plotted as percentage of the initial activity. 
Residual PON1 activity with no addition of TNM remained 
unchanged for all the samples (~100%). Data represents 
mean ± SD of 3 independent experiments performed in 
duplicates.
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the surviving animals exhibited adverse effects. Groups of
8 male C57BL/6J mice were treated with various test items
followed by intoxication with CPO. Atropine (20 mg/kg)
plus 2-PAM (25 mg/kg) served as a control treatment for
the prevention of OP toxicity [64]. Untreated mice, and
control mice treated with TBS buffer or POPC, showed
poor protection where all mice in these groups either died
or showed sever reaction and the clinical score was 3.6-3.9
(Table 1). In contrast, the administration of BL-3050 or
rePON1-TBS reduced dramatically the mortality and
severe reactions to 12.5% when given 3 hours prior to poi-
soning with score of 1.3-1.4, and 0-12.5% when rePON1-
TBS was given 14 hours prior to poisoning (score 1.1-1.8).
Strikingly, when rePON1 was administered at a higher
dose, better protection overall was observed (score 1.1
versus 1.8) when 62.5% of the mice had no reaction (data
not shown). In contrast to BL-3050 and rePON1-TBS, the
protection provided by atropine plus 2-PAM decreased as
the time gap between the treatment and OP poisoning
increased (score 0.5 versus 2.1). Indeed, prophylactic
activities of rePON1 were observed following IV adminis-
trations 5 minutes up to 14 hours prior to the OP expo-
sure, with optimal effects after 3 hours. However, for
reason that are unclear at present, at the longest duration
of pre-treatment (14 hrs), the protection by rePON1 on its
own was higher than for its HDL complex (BL-3050). The
latter provided only a limited protection (scores of 1.1-1.8
and 3.0, respectively). One possibility is, that upon the IV
administration, rePON1 can associate with endogenous
HDL particles that may stabilize it and slow its clearance
rate. Further pharmacokinetic studies may determine the
rate of clearance in blood, and shed light on the observed
differences.
Conclusion
This study shows the highly improved stability and activ-
ity of the engineered rePON1, and of its HDL complex
(rePON1-HDL and BL-3050), and their applicability in
vivo. RePON1 and BL-3050 are significantly more stable
than their human counterparts. Whilst the conditions
applied here only partly mimic the in vivo challenges, and
some conditions such as calcium chelators might not be
relevant in vivo, the fact that with the entire range of chal-
lenges tested here rePON1 was found to be more resistant
than huPON1, suggests that rePON1 would also be more
resistant against physiological challenges that relate to the
formation of dysfunctional HDL during atherosclerotic
and cardiovascular diseases [23]. The improved stability
of rePON1 might also be advantageous for long-term stor-
age, thus increasing the shelf-life of rePON1 based formu-
lations.
Furthermore, rePON1 described here was generated by
directed evolution for bacterial expression, and since it
differs from both human and mouse PON1s, it could have
created adverse immune responses when repeatedly
administrated. Yet, acute and repeated toxicology studies
suggested that rePON1 is a non toxic protein, and that BL-
3050 administrated IV is a safe particle that can be used
for acute treatment with no adverse effects and may also
be considered for repeated injections. The in vivo activity
of the improved rePON1 was demonstrated by using BL-
3050 and rePON1 for organophosphate poisoning pro-
tection compared to standard treatment of atropine and
2-PAM. The significant prophylactic effect was demon-
strated by rePON1 persisting at least 14 hours after its
administration. Furthermore, rePON1-TBS results for 14
hours may suggest a dose response where higher amount
of rePON1 provided a better protection. Also, these results
suggest that rePON1 and BL-3050 can be applied in vivo
while taking advantage of the improved stability and cat-
alytic efficiencies of rePON1 variant.
Notably, rePON1 administered here significantly differs
from the endogenous mouse PON1 (17% amino acid
divergence), similar to the case with human PON1 (15%
amino acid divergence). These results open the road for
the use of rePON1 variants that were evolved for
improved OP hydrolysis and can detoxify several com-
mon agents that huPON1 cannot [13,36,37]. Since the
efficacy of rePON1 and BL-3050 against OP poisoning
was similar, and because the phosphotriesterase activity of
rePON1 is barely stimulated by HDL, it seems that
rePON1 can be used as a detoxifying agent both in its free
and POPC-complexed form. On the other hand, the sig-
nificant (>20-fold) activation of the lactonase and antia-
therogenic activities of PON1 by reHDL [21,35] suggests
that rePON1-HDL complexes may also exhibit promising
antiatherogenic activities in vivo.
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